Avidity Biosciences, Inc.

NasdaqGM RNA

Avidity Biosciences, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -11.51

Avidity Biosciences, Inc. Price to Earnings Ratio (P/E) is -11.51 on January 14, 2025, a -197.95% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Avidity Biosciences, Inc. 52-week high Price to Earnings Ratio (P/E) is -3.59 on January 23, 2024, which is 68.78% above the current Price to Earnings Ratio (P/E).
Avidity Biosciences, Inc. 52-week low Price to Earnings Ratio (P/E) is -22.33 on November 13, 2024, which is -94.09% below the current Price to Earnings Ratio (P/E).
Avidity Biosciences, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -12.59.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: RNA

Avidity Biosciences, Inc.

CEO	Ms. Sarah Boyce
IPO Date	June 12, 2020
Location	United States
Headquarters	10578 Science Center Drive
Employees	253
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Key trends

Past 5 years